EUVIMEDEUVIMED entdecken
Crossref

Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium

Alessandra D'Amico iD, Vittorio Picchio iD, Patrizia Fabbi, Silvano Garibaldi iD, Cristina Nocella, Maurizio Forte iD, Flavio Di Nonno iD, Angela Leonardo iD, Emanuele Valeriani, Pasquale Pignatelli iD, Ernesto Greco iD, Giacomo Frati iD und 8 weitere

Journal of the American Heart Association · 18.11.2026

DOI: 10.1161/jaha.126.049175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 18.11.2026. Verfasst von Alessandra D'Amico und 19 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Neuromed Pozzilli Italy. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endothelial dysfunction is a hallmark of cardiovascular disease, driven by oxidative stress, inflammation, and platelet activation. We hypothesized that the FXa inhibitor rivaroxaban, alone or combined with clopidogrel, could counteract platelet‐induced oxidative injury to the endothelium and preserve endothelial function.

Methods

We conducted a prospective multicenter cohort clinical study in patients on chronic antiplatelet therapy (mostly aspirin) who initiated rivaroxaban, measuring indices of oxidative stress, endothelial function (nitric oxide bioavailability, ICAM‐1/VCAM‐1 levels), and platelet activation before and after rivaroxaban. In parallel, human endothelial cells were exposed to convulxin‐activated platelet supernatants from healthy donors with or without rivaroxaban±clopidogrel, and assessed for NOX2 expression/activity, adhesion molecules, nitric oxide (NO) production, and tube‐forming capacity. An ex vivo mouse model of angiotensin II–induced endothelial dysfunction was used to evaluate vascular relaxation responses after incubation with rivaroxaban and/or clopidogrel.

Results

Rivaroxaban significantly improved endothelial function in patients and in vitro, as shown by reduced endothelial ICAM‐1 and VCAM‐1 expression and increased NO availability despite platelet‐derived oxidative stress. Rivaroxaban also decreased H 2 O 2 production, downregulated endothelial NOX2 expression and sNOX2‐dp release, and restored angiogenic capacity in endothelial cells exposed to activated platelets. Clopidogrel alone had negligible effects on these parameters. Notably, adding clopidogrel to rivaroxaban provided no additional endothelial benefit beyond rivaroxaban monotherapy. In an ex vivo hypertensive vessel model, rivaroxaban (but not clopidogrel) markedly improved endothelium‐dependent relaxation.

Conclusions

Rivaroxaban effectively preserves endothelial function by inhibiting platelet‐induced NOX2‐mediated oxidative stress and inflammation. The lack of any additive benefit from clopidogrel suggests that rivaroxaban alone may be mechanistically sufficient to counteract platelet‐driven endothelial dysfunction. These findings reveal a novel vasoprotective mechanism for rivaroxaban and underscore its potential clinical value in mitigating vascular injury beyond its established antithrombotic effects.

Schlagwörter

Stichwörter der Autor:innen

NADPH oxidase 2 (NOX2)endothelial dysfunctionoxidative stressplatelet–endothelium interactions

Autor:innen und Institutionen

  • IRCCS Neuromed Pozzilli Italy.
  • Department of Medical and Surgical Sciences and Biotechnologies Sapienza University of Rome Latina Italy.
  • Department of Internal Medicine University of Genova Genoa Italy.
  • Department of Medical and Cardiovascular Sciences Sapienza University of Rome Rome Italy.
  • Istituto Pasteur Italia - Fondazione Cenci Bolognetti, Istituto Pasteur Italia Rome Italy.
  • Department of Health and Life Sciences European University of Rome Rome Italy.

ORCID-Profile: Alessandra D'Amico, Vittorio Picchio, Silvano Garibaldi, Maurizio Forte, Flavio Di Nonno, Angela Leonardo, Pasquale Pignatelli, Ernesto Greco, Giacomo Frati, Antonio Sili Scavalli, Martina Berteotti, Rossella Marcucci, Pietro Ameri, Roberto Carnevale, Italo Porto

Zitieren

APA

D'Amico, A., Picchio, V., Fabbi, P., Garibaldi, S., Nocella, C., Forte, M., Di Nonno, F., Leonardo, A., Valeriani, E., Pignatelli, P., Greco, E., Frati, G., Casciaro, G. E., Scavalli, A. S., Ciarrocca Taranta, G., Berteotti, M., Marcucci, R., Ameri, P., Carnevale, R., & Porto, I. (2026). Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.049175

Vancouver

D'Amico A, Picchio V, Fabbi P, Garibaldi S, Nocella C, Forte M, et al. Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.049175

BibTeX
@article{DAmico2026,
  author = {D'Amico, Alessandra and Picchio, Vittorio and Fabbi, Patrizia and Garibaldi, Silvano and Nocella, Cristina and Forte, Maurizio and Di Nonno, Flavio and Leonardo, Angela and Valeriani, Emanuele and Pignatelli, Pasquale and Greco, Ernesto and Frati, Giacomo and Casciaro, Giovanni Enrico and Scavalli, Antonio Sili and Ciarrocca Taranta, Giulia and Berteotti, Martina and Marcucci, Rossella and Ameri, Pietro and Carnevale, Roberto and Porto, Italo},
  title = {Rivaroxaban Inhibits Platelet‐Driven NOX2‐Dependent Oxidative Injury to Endothelium},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.049175}
}
Kostenlos starten →